BONESUPPORT Q2: The US growth spurt continues - Redeye

Redeye raises its base case for BONESUPORT following the Q2 2023 report, where our US CERAMENT G sales estimates were once again beaten. We reconsider our long-term sales outlook for CERAMENT G in the US while also assuming that the cannibalization of CERAMENT BVF will be more aggressive than previously expected.

Länk till analysen i sin helhet: https://www.redeye.se/research/922112/bonesupport-q2-the-us-growth-spurt-continues?utm_source=finwire&utm_medium=RSS